(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.47%) $79.63
(0.39%) $2.31
(0.58%) $2 353.80
(0.88%) $28.62
(0.22%) $993.00
(-0.31%) $0.927
(-0.40%) $10.85
(-0.25%) $0.798
(0.87%) $92.54
Quarter results today
(amc 2024-05-09)
Expected move: +/- 0.00%
1.72% $ 1.180
Live Chart Being Loaded With Signals
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally...
Stats | |
---|---|
Tagesvolumen | 705 131 |
Durchschnittsvolumen | 973 222 |
Marktkapitalisierung | 222.78M |
EPS | $0 ( 2024-03-07 ) |
Nächstes Ertragsdatum | ( $-0.0400 ) 2024-06-11 |
Last Dividend | $0.0800 ( 2003-12-15 ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.83 |
ATR14 | $0.00500 (0.43%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-07 | Culley Brian M | Buy | 1 900 000 | Employee Stock Option (Right to Buy) |
2024-03-07 | Samuel George A. Iii | Buy | 650 000 | Employee Stock Option (Right to Buy) |
2024-03-07 | Howe Jill Ann | Buy | 650 000 | Employee Stock Option (Right to Buy) |
2024-02-11 | Samuel George A. Iii | Sell | 6 076 | Restricted Stock Units |
2024-02-11 | Samuel George A. Iii | Buy | 6 076 | Common Shares, no par value |
INSIDER POWER |
---|
98.19 |
Last 93 transactions |
Buy: 20 710 358 | Sell: 1 476 683 |
Volumen Korrelation
Lineage Cell Therapeutics Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Lineage Cell Therapeutics Korrelation - Währung/Rohstoff
Lineage Cell Therapeutics Finanzdaten
Annual | 2023 |
Umsatz: | $8.95M |
Bruttogewinn: | $7.58M (84.76 %) |
EPS: | $-0.120 |
FY | 2023 |
Umsatz: | $8.95M |
Bruttogewinn: | $7.58M (84.76 %) |
EPS: | $-0.120 |
FY | 2022 |
Umsatz: | $14.70M |
Bruttogewinn: | $13.98M (95.05 %) |
EPS: | $-0.160 |
FY | 2021 |
Umsatz: | $3.90M |
Bruttogewinn: | $2.47M (63.40 %) |
EPS: | $-0.260 |
Financial Reports:
No articles found.
Lineage Cell Therapeutics Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0800 | 2003-12-15 |
Last Dividend | $0.0800 | 2003-12-15 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.0800 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
DFUS | Ex Dividend Junior | 2023-09-19 | Quarterly | 0 | 0.00% | |
IHT | Ex Dividend Knight | 2023-07-19 | Semi-Annually | 0 | 0.00% | |
PRK | Ex Dividend Knight | 2023-08-17 | Quarterly | 0 | 0.00% | |
GLV | Ex Dividend Knight | 2023-09-21 | Monthly | 0 | 0.00% | |
NTIP | Ex Dividend Junior | 2023-09-18 | Semi-Annually | 0 | 0.00% | |
CQP | Ex Dividend Knight | 2023-08-04 | Quarterly | 0 | 0.00% | |
FRD | Ex Dividend Knight | 2023-10-19 | Quarterly | 0 | 0.00% | |
NEN | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% | |
WTV | Ex Dividend Junior | 2023-06-26 | Quarterly | 0 | 0.00% | |
CET | Ex Dividend Knight | 2023-06-09 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -2.41 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.213 | 1.200 | -7.10 | -8.52 | [0 - 0.3] |
returnOnEquityTTM | -0.313 | 1.500 | -4.59 | -6.89 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.14 | 0.800 | 4.30 | 3.44 | [1 - 3] |
quickRatioTTM | 2.02 | 0.800 | 2.84 | 2.27 | [0.8 - 2.5] |
cashRatioTTM | 1.973 | 1.500 | 0.148 | 0.222 | [0.2 - 2] |
debtRatioTTM | 0.0292 | -1.500 | 9.51 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 56.86 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.165 | 2.00 | -0.0551 | -0.110 | [0 - 30] |
freeCashFlowPerShareTTM | -0.169 | 2.00 | -0.0847 | -0.169 | [0 - 20] |
debtEquityRatioTTM | 0.0465 | -1.500 | 9.81 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.905 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -2.77 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -9.68 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0885 | 0.800 | -2.74 | -2.19 | [0.5 - 2] |
Total Score | -0.295 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -9.31 | 1.000 | -1.041 | 0 | [1 - 100] |
returnOnEquityTTM | -0.313 | 2.50 | -2.95 | -6.89 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.169 | 2.00 | -0.0564 | -0.169 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.165 | 2.00 | -0.0551 | -0.110 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0603 | 1.500 | -2.93 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -3.19 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.30 |
Lineage Cell Therapeutics
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.